I'll research this company to build the profile.
Let me dig deeper into the specific Malta entity and its role.
Let me verify the corporate ownership chain (Watson/Actavis/Teva) and confirm this is distinct from the medical-device Arrow International.
Arrow International Limited (commonly "Arrow") is a Malta-incorporated company that appears in U.S. patent litigation as Natco Pharma's U.S. marketing partner and, later, the holder of the ANDA for generic lenalidomide (Revlimid). Court filings and an FTC complaint identify it as a Malta limited liability company with a principal place of business at 57 St. Christopher Street, Valletta; a Maltese company registry aggregator lists it at Luqa, Malta. It is distinct from the U.S. medical-device maker Arrow International, Inc. (Reading, PA, now a Teleflex subsidiary). Arrow was part of the "Arrow Group" (holding company Robin Hood Holdings Limited), a privately held international generics group founded by Tony Tabatznik; Watson Pharmaceuticals acquired the group for ~$1.75 billion in a deal announced June 2009 and closed in December 2009. Watson later became Actavis, whose generics business was acquired by Teva Pharmaceutical Industries Ltd. in 2016, and Arrow International Limited is now described in Natco's own press releases as an affiliate of Teva.
Operations. Arrow is a generic-pharmaceuticals commercial and distribution entity, not an R&D-stage or NPE shell. At acquisition, the broader Arrow Group marketed more than 100 molecules across 20-plus countries and ran manufacturing operations in Malta, Canada and Brazil, with roughly 1,000 employees and 2008 revenue of approximately $647 million (Watson press release). Within that group, Arrow International Limited served as the U.S. commercialization vehicle/marketing partner for partners such as Natco; in August 2021 Natco transferred the lenalidomide ANDA to Arrow International Limited.
Litigation posture. The structured data shows one tracked case, as a defendant — consistent with an operating commercial entity defending an ANDA patent suit rather than a patent-assertion entity. Celgene Corporation v. Natco Pharma Ltd. et al. (D.N.J., filed 2012) was a Hatch-Waxman infringement action naming Arrow alongside Natco and Watson Laboratories.
Notable case/context. That suit settled in December 2015 via consent judgment; the settlement gave Natco/Arrow a volume-limited U.S. license beginning March 2022 and an unlimited license from January 31, 2026. Natco and Arrow launched the first U.S. generic Revlimid in March 2022. The same settlement has since drawn antitrust scrutiny in separate purchaser suits alleging a reverse-payment arrangement.